MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why OCGN Stock dropped -4.15% Today — RQD Quant Desk Flash
$0.74 -4.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.73
Ocugen Inc. (OCGN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $252.4M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.73 (-0.94%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OCGN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY OCGN SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (31% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (23% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.96-18.7% Next Q
43
Q2 (-2Q)Grade D$0.78-5.1% Next Q
40
Q3 (-1Q)Grade E$0.74+0% Next Q
38
CurrentGrade D-$0.74-8.5% Hist 90D α
35
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a OCGN Turnaround Squeeze
While OCGN currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.03) and Max Pain ($0.78) forces dealer call-delta covering toward $2.87.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $OCGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OCGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why OCGN Stock dropped -4.15% Today — RQD Quant Desk Flash
Ocugen Inc. (OCGN) dropped -4.15% to $0.74, trading at 2% of its 52-week range ($0.69 – $2.73). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.69 – $2.73) with RSI-14 at 28.3 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.74 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live OCGN Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OCGN)
- ✓Walkthrough of OCGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OCGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.23%▼ SUPPORT BREAKDOWN
2026-10-30O $0.75H $0.76L $0.69C $0.74VOL 5.41M
RES: $1.20SUP: $0.78SMA50: $1.03SMA200: $1.43
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
OCGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +8.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on OCGN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for OCGN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OCGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OCGN)
Health Care Rank #818 of 1016
⚔️ LXEO vs OCGN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (OCGN vs. LXEO, FATE, LCTX, IPSC)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Ocugen Inc. (OCGN) ranks #818 by composite RQD confidence (35/100, grade D-) and #546 by equity capitalization ($252.4M). Within this direct 5-issuer industry benchmark cohort, OCGN leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. FATE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with OCGN at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OCGN
ACTIVE
Ocugen Inc. | D- | 35/100 | — | — | -35.0% | -4.15% | $252.4M | Benchmark Subject |
| LXEO Lexeo Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -2.24% | $251.1M | /lxeo-vs-ocgn → |
| FATE Fate Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | 0.00% | $260.0M | /fate-vs-ocgn → |
| LCTX Lineage Cell Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -0.96% | $260.5M | /lctx-vs-ocgn → |
| IPSC Century Therapeutics Inc. | E | 28/100 | — | — | -14.1% | -2.67% | $264.4M | /ipsc-vs-ocgn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001372299In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ocugen Inc. (OCGN) reported GAAP revenue of $4.4M (+8.8% vs. FY2024 revenue of $4.1M , and -26.9% cumulative change since FY2023) , GAAP net income of -$68.0M, operating cash flow of -$57.0M, and free cash flow of -$57.1M (-25.5% YoY). On the balance sheet, OCGN closed FY2025 with $43.5M in total assets against $27.5M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $4.4M | -$68.0M | -$57.0M | -$57.1M | $43.5M | $27.5M |
| FY2024 (FY) | 2024-12-31 | $4.1M | -$54.0M | -$42.1M | -$45.5M | $82.4M | $27.3M |
| FY2023 (FY) | 2023-12-31 | $6.0M | -$63.0M | -$62.1M | -$62.1M | — | — |
3. OCGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OCGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Ocugen Inc. (NASDAQ: OCGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.74 (-4.15% 1D, market cap $252.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OCGN ranks #818 in composite RQD confidence.
How does OCGN compare to LXEO and FATE in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), OCGN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LXEO (Lexeo Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $251.1M) and FATE (Fate Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $260.0M). Among the 5-stock peer group, OCGN leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OCGN?
Per OCGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001372299), Ocugen Inc. generated $4.4M in revenue (+8.8% YoY), -$68.0M in net income, and -$57.1M in free cash flow against $43.5M in total assets and $27.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OCGN trading relative to its 50-day, 200-day, and 52-week technical levels?
OCGN last traded at $0.74 (-4.15% on volume of 5,534,074 shares), positioning the stock -28.16% below its 50-day simple moving average ($1.03) and -48.25% below its 200-day simple moving average ($1.43). Across its 52-week range of $0.69 to $2.73, OCGN sits at the 2.5% percentile with a 14-day RSI of 28.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.83).
OCGN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is OCGN stock moving today?
Why OCGN Stock dropped -4.15% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.